Published: Just now
Now the Public Health Agency is pausing the covid-19 vaccine Nuvaxovid for people under 31. The reason is signs of an increased risk of heart muscle inflammation.
People who are 30 years old and younger should no longer be given the covid-19 vaccine Nuvaxovid, recommends the Public Health Agency. The background to the decision is that data from Australia has shown an increased incidence of myocarditis and pericarditis in connection with the vaccine, especially in younger people. The vaccine can still be given as a primary dose or top-up dose to people aged 31 and over, according to the Public Health Authority.
In Sweden, approximately 7,000 doses of Nuvaxovid have been given, so it is not a matter of use to any great extent, writes the Public Health Agency.
“We are following the situation closely and are awaiting more data. But those who are younger and recently vaccinated with Nuvaxovid need not worry. The risk is very small and you can continue with the next dose with another vaccine,” says Sören Andersson, head of the vaccination program unit, in a press release.
The decision applies from today, Thursday, and is temporary, the authority writes on its website.